Downregulation of CD9 protein expression is associated with aggressive behavior of oral squamous cell carcinoma

Oral Oncology

Volumn 46, Issue 3, 2010, Pages 166-171

  Buim, Marcilei Eliza Cavicchioli ^a   Lourenço, Silvia Vanessa ^b   Carvalho, Kátia Candido ^a   Cardim, Roberta ^a   Pereira, Cláudia ^a   Carvalho, André Lopes ^c   Fregnani, José Humberto ^c   Soares, Fernando Augusto ^a,b  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c BARRETOS CANCER HOSPITAL   (Brazil)

Author keywords

CD82; CD9; Immunohistochemistry; Oral squamous carcinoma; Tetraspanin

Indexed keywords

CD37 ANTIGEN; CD63 ANTIGEN; CD81 ANTIGEN; CD82 ANTIGEN; CD9 ANTIGEN; TETRASPANIN;

ADULT; AGED; ARTICLE; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ANTIGENS, CD; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KANGAI-1 PROTEIN; LYMPHATIC METASTASIS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PLATELET MEMBRANE GLYCOPROTEINS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS;

EID: 76749153352     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2009.11.009     Document Type: Article

References (31)

1. Kawano K., and Yanagisawa S. Predictive value of laminin-5 and membrane type 1-matrix metalloproteinase expression for cervical lymph node metastasis in T1 and T2 squamous cell carcinomas of the tongue and floor of the mouth. Head Neck 28 6 (2006) 525-533
2. Longo N., Yanez-Mo M., Mittelbrunn M., de la Rosa G., Munoz M.L., Sanchez-Madrid F., et al. Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood 98 13 (2001) 3717-3726
3. Erovic B.M., Pammer J., Hollemann D., Woegerbauer M., Geleff S., Fischer M.B., et al. Motility-related protein-1/CD9 expression in head and neck squamous cell carcinoma. Head Neck 25 10 (2003) 848-857
4. van Spriel A.B., Puls K.L., Sofi M., Pouniotis D., Hochrein H., Orinska Z., et al. A regulatory role for CD37 in T cell proliferation. J Immunol 172 5 (2004) 2953-2961
5. Levy S., Todd S.C., and Maecker H.T. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 16 (1998) 89-109
6. Saito Y., Tachibana I., Takeda Y., Yamane H., He P., Suzuki M., et al. Absence of CD9 enhances adhesion-dependent morphologic differentiation, survival, and matrix metalloproteinase-2 production in small cell lung cancer cells. Cancer Res 66 (2006) 9557-9565
7. Huang C.I., Kohno N., Ogawa E., Adachi M., Taki T., and Miyake M. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol 153 3 (1998) 973-983
8. Boucheix C., and Rubinstein E. Tetraspanins. Cell Mol Life Sci 58 9 (2001) 1189-1205
9. Mhawech P., Herrmann F., Coassin M., Guillou L., and Iselin C.E. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression. Cancer 98 8 (2003) 1649-1657
10. Sauer G., Windisch J., Kurzeder C., Heilmann V., Kreienberg R., and Deissler H. Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res 9 17 (2003) 6426-6431
11. Kusukawa J., Ryu F., Kameyama T., and Mekada E. Reduced expression of CD9 in oral squamous cell carcinoma: CD9 expression inversely related to high prevalence of lymph node metastasis. J Oral Pathol Med 30 2 (2001) 73-79
12. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29 (2001) 45
13. Adachi M., Taki T., Konishi T., Huang C.I., Higashiyama M., and Miyake M. Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression. J Clin Oncol 16 4 (1998) 1397-1406
14. Sho M., Adachi M., Taki T., Hashida H., Konishi T., Huang C.L., et al. Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int J Cancer 79 5 (1998) 509-516
15. Chen Z., Mustafa T., Trojanowicz B., Brauckhoff M., Gimm O., Schmutzler C., et al. CD82 and CD63 in thyroid cancer. Int J Mol Med 14 4 (2004) 517-527
16. Hotta H., Ross A.H., Huebner K., Isobe M., Wendeborn S., Chao M.V., et al. Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Res 48 11 (1988) 2955-2962
17. Radford K.J., Mallesch J., and Hersey P. Suppression of human melanoma cell growth and metastasis by the melanoma-associated antigen CD63 (ME491). Int J Cancer 62 5 (1995) 631-635
18. Ikeyama S., Koyama M., Yamaoko M., Sasada R., and Miyake M. Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med 177 5 (1993) 1231-1237
19. Dong J.T., Lamb P.W., Rinker-Schaeffer C.W., Vukanovic J., Ichikawa T., Isaacs J.T., et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268 5212 (1995) 884-886
20. Yu Y., Yang J.L., Markovic B., Jackson P., Yardley G., Barrett J., et al. Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers. Clin Cancer Res 3 7 (1997) 1045-1049
21. Lombardi D.P., Geradts J., Foley J.F., Chiao C., Lamb P.W., and Barrett J.C. Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res 59 22 (1999) 5724-5731
22. Uchida S., Shimada Y., Watanabe G., Li Z.G., Hong T., Miyake M., et al. Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer 79 7-9 (1999) 1168-1173
23. Miyazaki T., Kato H., Shitara Y., Yoshikawa M., Tajima K., Masuda N., et al. Mutation and expression of the metastasis suppressor gene KAI1 in esophageal squamous cell carcinoma. Cancer 89 5 (2000) 955-962
24. Liu F.S., Dong J.T., Chen J.T., Hsieh Y.T., Ho E.S., Hung M.J., et al. KAI1 metastasis suppressor protein is down-regulated during the progression of human endometrial cancer. Clin Cancer Res 9 4 (2003) 1393-1398
25. Uzawa K., Ono K., Suzuki H., Tanaka C., Yakushiji T., Yamamoto N., et al. High prevalence of decreased expression of KAI1 metastasis suppressor in human oral carcinogenesis. Clin Cancer Res 8 3 (2002) 828-835
26. Farhadieh R.D., Smee R., Ow K., Yang J.L., Russell P.J., Crouch R., et al. Down-regulation of KAI1/CD82 protein expression in oral cancer correlates with reduced disease free survival and overall patient survival. Cancer Lett 213 1 (2004) 91-98
27. Imai Y., Sasaki T., Shinagawa Y., Akimoto K., and Fujibayashi T. Expression of metastasis suppressor gene (KAI1/CD82) in oral squamous cell carcinoma and its clinico-pathological significance. Oral Oncol 38 6 (2002) 557-561
28. Sakamoto K., Nakamura Y., and Nakashima T. Immunohistochemical distribution of CD9 in parotid gland tumors. Auris Nasus Larynx 31 1 (2004) 49-55
29. Miyamoto S., Maruyama A., Okugawa K., Akazawa K., Baba H., Maehara Y., et al. Loss of motility-related protein 1 (MRP1/CD9) and integrin alpha3 expression in endometrial cancers. Cancer 92 3 (2001) 542-548
30. Funakoshi T., Tachibana I., Hoshida Y., et al. Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer. Oncogene 22 5 (2003) 674-687
31. Wang J.C., Begin L.R., Berube N.G., Chevalier S., Aprikian A.G., Gourdeau H., et al. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications. Clin Cancer Res 13 18 (2007) 2354-2361